Paying users zone. Data is covered by 
.
Get to Regeneron Pharmaceuticals Inc. for $15.99, or
get to entire website for at least 3 months from $49.99.
Enterprise Value (EV)
Difficulty: Intermediate
Current Enterprise Value (EV)
Regeneron Pharmaceuticals Inc., current enterprise value calculation
| Current share price (P) | $ |
| No. shares of common stock outstanding | |
| USD $ in thousands | |
| Common equity (market value) | |
| Add: Preferred Stock, $.01 par value; issued and outstanding - none (per books) | |
| Total equity | |
| Add: Capital and facility lease obligations, current portion (per books) | |
| Add: Convertible senior notes, current portion (per books) | |
| Add: Capital and facility lease obligations, excluding current portion (per books) | |
| Add: Convertible senior notes, excluding current portion (per books) | |
| Total equity and debt | |
| Less: Cash and cash equivalents | |
| Less: Marketable securities | |
| Enterprise value (EV) | |
Based on: 10-K (filing date: 2019-02-07).
Historical Enterprise Value (EV)
Regeneron Pharmaceuticals Inc., EV calculation
Based on: 10-K (filing date: 2019-02-07), 10-K (filing date: 2018-02-08), 10-K (filing date: 2017-02-09), 10-K (filing date: 2016-02-11), 10-K (filing date: 2015-02-12).
1 Data adjusted for splits and stock dividends.
2 Close price on the filing date of Regeneron Pharmaceuticals Inc.’s Annual Report.
| Item | Description | The company |
|---|---|---|
| EV | Enterprise value is total company value (the market value of common equity, debt, and preferred equity) minus the value of cash and short-term investments. | Regeneron Pharmaceuticals Inc.’s EV declined from 2016 to 2017 but then increased from 2017 to 2018 exceeding 2016 level. |